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Abstract
Soluble  molecules  of  the  major  histocompatibility  complex  play  an  important  role  in  the
development of various immune-mediated diseases. However, there is not much information on
the participation of these proteins in the pathogenesis of chronic obstructive pulmonary disease
(COPD). The aim of our work was to determine the content of soluble molecules of the major
histocompatibility  complex  of  classes  I  and  II  (sHLA-I  and  sHLA-II)  in  the  exhaled  breath
condensate (EBC) and in the blood serum in patients with moderate to severe COPD during the
exacerbation and stable phase. We investigated 105 patients (male) with COPD aged 46-67 and
21 healthy nonsmoking volunteers (male) comparable in age. The content of sHLA-I and sHLA-II
molecules was studied using ELISA. We found an increase in the level of sHLA-I and sHLA-II
molecules  in  EBC,  as  well  as  an enhancement  in  the serum content  of  sHLA-II  in  all  the
examined COPD patients compared to healthy nonsmoking volunteers. The revealed negative
correlation between the serum concentration of sHLA-II and values of FEV1 and FEV1/FVC in all
examined patients with COPD gives a possibility to consider the content of these proteins as an
additional  systemic  marker  of  disease  severity.  The  maximum  endobronchial  and  serum
concentrations of sHLA-I and sHLA-II were detected in patients with severe COPD during the
exacerbation. The negative associations between the content of these molecules in EBC and
serum and the parameters of lung function in patients with severe COPD were established.
These findings suggest a pathogenetic role of sHLA-I and sHLA-II molecules in the mechanisms
of the development and progression of local and systemic inflammation in COPD.
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